Component
Measured human nicotine plasma exposure AUC
Measured human nicotine plasma exposure AUC. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
The clinical trial found no significant nicotine AUC change with the characterized C. verum regimen; the geometric mean exposure ratio was 0.98.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/ceylon-research/41622703.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0d12141499aba319f8c7513f708889a4dc40fae628e26600f780be2323fe0db3", "start_char": 0, "end_char": 1643, "text_sha256": "0d12141499aba319f8c7513f708889a4dc40fae628e26600f780be2323fe0db3"}
- experimental_model
- Within-person clinical pharmacokinetic comparison
- exposure
- Characterized C. verum 2 g three times daily for five days, with day-six drug coadministration and two further cinnamon doses; nicotine gum 2 mg or letrozole 2.5 mg
- limitations
- Product- and regimen-specific short-term result, not proof of no interaction with all drugs, oils or extracts. CYP2A6 model predictions did not translate into large AUC changes here.
- nutrient_topic
- Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect. · Ceylon cinnamon / Cinnamomum verum bark preparations
- organism
- Human
- plain_language
- The large interaction predicted from enzyme models was not seen for nicotine in this human study.
- primary_references
- [ceylon-p41622703] Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio. (2026). https://pubmed.ncbi.nlm.nih.gov/41622703/ DOI: 10.1002/cpt.70218
- tissue_or_cell_type
- 16 healthy non-nicotine-using adults; plasma drug profiles
Ceylon cinnamon: metabolism, signaling and nutrient connections (2026-09-17) · lines 1195–1206
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Within-person clinical pharmacokinetic comparison · source_derived_draft · unverified_draft
### ceylon-nicotine-clinical The clinical trial found no significant nicotine AUC change with the characterized C. verum regimen; the geometric mean exposure ratio was 0.98. Condition category: normal nutrient_topic: Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect. plain_language: The large interaction predicted from enzyme models was not seen for nicotine in this human study. organism: Human tissue_or_cell_type: 16 healthy non-nicotine-using adults; plasma drug profiles experimental_model: Within-person clinical pharmacokinetic comparison limitations: Product- and regimen-specific short-term result, not proof of no interaction with all drugs, oils or extracts. CYP2A6 model predictions did not translate into large AUC changes here. exposure: Characterized C. verum 2 g three times daily for five days, with day-six drug coadministration and two further cinnamon doses; nicotine gum 2 mg or letrozole 2.5 mg evidence_span: {"source_cache": "artifacts/ceylon-research/41622703.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0d12141499aba319f8c7513f708889a4dc40fae628e26600f780be2323fe0db3", "start_char": 0, "end_char": 1643, "text_sha256": "0d12141499aba319f8c7513f708889a4dc40fae628e26600f780be2323fe0db3"} [ceylon-p41622703] Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio. (2026). https://pubmed.ncbi.nlm.nih.gov/41622703/ DOI: 10.1002/cpt.70218
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.